H.C. Wainwright analyst Douglas Tsao initiated coverage of Viridian Therapeutics with a Buy rating and $35 price target. The analyst says the company is well positioned for leadership in the over $2B thyroid eye disease market. He think Viridian’s portfolio of IGF-1R antagonist mAbs offers competitive advantages which give it an opportunity to challenge Horizon’s Tepezza.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VRDN:
- Viridian Therapeutics reports Q3 EPS (86c), consensus (95c)
- Viridian Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Updates
- Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)
- Viridian Therapeutics to Participate in Guggenheim 4th Annual Neuro/Immunology Conference on November 15th
- Viridian Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 14, 2022